Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
U.K.’s CRT To Develop Lorus Cancer Drug
by Lisa M. Jarvis
December 3, 2012
| A version of this story appeared in
Volume 90, Issue 49
Cancer Research Technology, the commercial arm of the nonprofit Cancer Research UK, will initiate a clinical trial for IL-17E, a Lorus Therapeutics cancer treatment. IL-17E is the third biologic that CRT has brought into its portfolio as part of a program that allows companies to keep the rights to drugs that the nonprofit evaluates. CRT will fund both preclinical and Phase I studies. If Lorus does not elect to continue developing IL-17E after seeing Phase I data, rights will be transferred to CRT.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter